The University of Alabama Capstone College of Nursing has unveiled groundbreaking research at the 2025 Diabetic Limb Salvage (DLS) Conference, showcasing the Benova Mouth Rinse System's ability to reduce tumor necrosis factor-alpha (TNFα) levels by 17% within just two minutes of application. This discovery is pivotal for millions suffering from inflammatory oral conditions, including cancer patients undergoing chemotherapy, where oral mucositis affects approximately 51% of individuals.
Dr. Daniel J. Gibson, a specialist in tissue fate determination, presented the study titled 'A Mechanism of Action of an Inflammatory Cytokine Inhibiting Solution.' The research highlights the Benova Mouth Rinse System's fast-acting anti-inflammatory effects in an in vitro model of inflamed oral mucosa, simulating conditions seen in patients with chronic inflammatory wounds or those receiving cancer therapy. Unlike traditional treatments, Benova achieves these results without lidocaine, steroids, or prescription medications, marking a significant advancement in oral care.
Bill Kling, co-founder of Benova, expressed enthusiasm over the correlation between the study's findings and anecdotal evidence from users who report rapid pain relief and healing of oral ulcers. The presentation at the DLS Conference, a key event for wound care and tissue regeneration specialists, underscores the potential of Benova to revolutionize treatment approaches for diabetic foot and limb wounds, among other conditions.
The implications of this study are vast, offering a new, efficient solution for managing pain and inflammation associated with oral mucositis and recurrent aphthous stomatitis (RAS), conditions that significantly impact quality of life. With TNFα playing a central role in inflammation and cell damage, the ability to quickly reduce its levels presents a promising avenue for enhancing patient care and outcomes in both oncology and general dentistry.
For further details on the study's findings, the full scientific rationale and poster are accessible, providing deeper insights into the mechanism behind Benova's anti-inflammatory action.
